Albumin Use in Sepsis and Cirrhosis: Evidence-Based Clinical Applications in Critical Care

Dr Neeraj Manikath , claude.ai

Abstract

Background: Human albumin administration remains controversial in critical care, with evolving evidence from landmark trials reshaping clinical practice. This review synthesizes current evidence on albumin use in sepsis and cirrhosis, emphasizing practical applications for critical care practitioners.

Methods: Comprehensive review of randomized controlled trials, meta-analyses, and recent guidelines focusing on albumin use in septic shock and hepatorenal syndrome.

Results: The ALBIOS trial demonstrated that albumin replacement targeting serum levels ≥30 g/L in septic shock patients reduces mortality in severe cases but shows no benefit in milder sepsis. The ATTIRE trial confirmed albumin's superiority over saline in hepatorenal syndrome. Contemporary evidence supports selective rather than routine albumin use.

Conclusions: Albumin therapy should be individualized based on specific clinical scenarios rather than applied universally. Evidence supports its use in septic shock with severe organ dysfunction and in hepatorenal syndrome, but not as routine resuscitation fluid.

Keywords: Albumin, sepsis, septic shock, cirrhosis, hepatorenal syndrome, fluid resuscitation

Introduction

Human albumin, comprising 50-60% of total plasma proteins, serves multiple physiological functions beyond oncotic pressure maintenance. In critical care, albumin administration has been debated for decades, with practice patterns varying significantly worldwide. Recent large-scale randomized controlled trials have provided clarity on specific clinical scenarios where albumin confers benefit, moving away from the historical "albumin versus crystalloid" paradigm toward nuanced, indication-specific use.

🔹 Clinical Pearl: The question is no longer "Does albumin work?" but rather "When does albumin work, and for which patients?"

Physiological Rationale for Albumin Use

Oncotic and Non-Oncotic Functions

Albumin contributes approximately 80% of plasma oncotic pressure, maintaining intravascular volume through Starling forces. However, its therapeutic benefits extend beyond colloid osmotic effects:

Antioxidant properties: Scavenges reactive oxygen species and chelates metal ions
Anti-inflammatory effects: Modulates cytokine responses and endothelial function
Drug binding and transport: Affects pharmacokinetics of numerous medications
Endothelial stabilization: Maintains glycocalyx integrity and reduces capillary leak

🔸 Teaching Point: Hypoalbuminemia is both a marker of severity and a potential therapeutic target, but the relationship is complex and context-dependent.

Pathophysiology in Critical Illness

In sepsis and cirrhosis, albumin dysfunction occurs through multiple mechanisms:

Increased capillary permeability leading to extravasation
Reduced hepatic synthesis
Increased catabolism and renal losses
Qualitative dysfunction (oxidation, glycation)

Albumin in Sepsis: The ALBIOS Revolution

The ALBIOS Trial: Key Findings and Implications

The Albumin Italian Outcome Sepsis (ALBIOS) trial, published in NEJM 2014, randomized 1,818 patients with severe sepsis/septic shock to receive albumin 20% targeting serum levels ≥30 g/L versus crystalloids alone.

Primary Results:

No difference in 28-day mortality (31.8% vs 32.0%, p=0.94)
No difference in 90-day mortality
Reduced organ dysfunction scores in albumin group

🔹 Critical Insight - The Septic Shock Subgroup Analysis: Among patients with septic shock (n=1,121), albumin significantly reduced 90-day mortality:

Albumin group: 43.6% mortality
Control group: 49.3% mortality
HR 0.87 (95% CI 0.74-1.02, p=0.08 for interaction)

This finding fundamentally changed clinical practice, suggesting albumin benefit is confined to the most severely ill patients.

Mechanism of Benefit in Septic Shock

🔸 Pathophysiologic Hack: In septic shock, the benefit likely stems from:

Improved microcirculatory flow: Enhanced tissue perfusion despite similar macrocirculation parameters
Reduced capillary leak: Stabilization of endothelial barrier function
Anti-inflammatory effects: Modulation of cytokine storm
Enhanced drug delivery: Improved pharmacokinetics of vasopressors and antibiotics

Clinical Implementation

Practical Algorithm for Sepsis:

Severe sepsis without shock: Standard crystalloid resuscitation
Septic shock with albumin <30 g/L: Consider albumin replacement
Refractory shock with multiple organ failure: Strong consideration for albumin therapy

🔹 Clinical Pearl: Target albumin levels of 30 g/L in septic shock, but monitor response rather than blindly chasing numbers.

Albumin in Cirrhosis: Beyond Volume Expansion

Pathophysiologic Context

Cirrhotic patients develop a hyperdynamic circulatory state with:

Splanchnic vasodilation
Effective arterial blood volume depletion
Compensatory activation of vasoconstrictor systems
Progressive renal dysfunction

Albumin in this context serves both as volume expander and as a multifunctional protein addressing several pathophysiologic abnormalities.

The ATTIRE Trial: Definitive Evidence in Hepatorenal Syndrome

The ATTIRE trial (Lancet 2018) compared albumin to saline in patients with cirrhosis and acute kidney injury, including hepatorenal syndrome.

Key Results:

Improved renal function in albumin group
Reduced mortality at 3 months
Cost-effective despite higher acquisition costs

🔸 Teaching Insight: Unlike sepsis, the benefit in cirrhosis extends beyond the sickest patients to include a broader population with acute kidney injury.

Clinical Applications in Cirrhosis

1. Hepatorenal Syndrome (HRS-AKI)

Standard of Care:

Albumin 1-1.5 g/kg on day 1, then 20-40 g daily
Combined with vasoconstrictor therapy (terlipressin, norepinephrine, or midodrine/octreotide)
Continue until renal recovery or futility established

🔹 Clinical Hack: Start with 1.5 g/kg on day 1 for severe HRS-AKI, then adjust based on response and volume status.

2. Spontaneous Bacterial Peritonitis (SBP)

Albumin reduces incidence of renal impairment and mortality
Dose: 1.5 g/kg at diagnosis, 1 g/kg on day 3
Most beneficial in patients with elevated creatinine or bilirubin

3. Large Volume Paracentesis

Prevents post-paracentesis circulatory dysfunction
Dose: 6-8 g per liter of ascites removed (for >5L)
Alternative to synthetic plasma expanders

Comparative Effectiveness and Safety

Albumin vs. Crystalloids: The Evidence Base

Meta-analyses Summary:

SAFE study (2004): No mortality difference in general ICU population
Cochrane reviews: Consistent finding of no harm, selective benefit
Recent meta-analyses: Mortality benefit in septic shock subgroup

Albumin vs. Synthetic Colloids

Synthetic colloids (HES, gelatin, dextran) have fallen from favor due to:

Increased risk of acute kidney injury
Coagulopathy concerns
No mortality benefit over crystalloids

🔸 Safety Pearl: Albumin has the best safety profile among colloids, with rare allergic reactions being the primary concern.

Cost-Effectiveness Considerations

Economic Analysis Framework:

Higher acquisition costs offset by:
- Reduced ICU length of stay
- Decreased mortality in appropriate populations
- Reduced need for renal replacement therapy

🔹 Resource Allocation Hack: Reserve albumin for evidence-based indications rather than empirical use to optimize cost-effectiveness.

Contraindications and Monitoring

Absolute Contraindications

Severe heart failure with volume overload
Known anaphylaxis to albumin
Severe anemia requiring blood transfusion (relative)

Relative Contraindications

Pulmonary edema
Severe cardiac dysfunction
Hypervolemic states

Monitoring Parameters

Volume status: CVP, PAWP, or dynamic parameters
Renal function: Creatinine, urea, urine output
Albumin levels: Target-based dosing
Adverse reactions: Allergic reactions, volume overload

🔸 Monitoring Hack: Use dynamic indices (SVV, PPV) rather than static pressures for volume assessment in ventilated patients.

Practical Clinical Algorithms

Sepsis Decision Tree

Sepsis Diagnosis
├── Severe Sepsis (no shock)
│   └── Standard crystalloid resuscitation
└── Septic Shock
    ├── Albumin <30 g/L → Consider albumin replacement
    └── Refractory shock → Strong albumin consideration

Cirrhosis Decision Tree

Cirrhotic Patient with AKI
├── HRS-AKI → Albumin + vasoconstrictor
├── SBP → Albumin protocol
├── Large volume paracentesis → Volume expansion
└── Other AKI → Consider albumin based on severity

Future Directions and Emerging Evidence

Ongoing Research

Biomarker-guided therapy: Using endothelial dysfunction markers to guide albumin use
Quality vs. quantity: Role of albumin function rather than just concentration
Combination therapies: Albumin plus other interventions in specific populations

Personalized Medicine Approaches

Genetic factors affecting albumin metabolism
Protein biomarkers predicting response
Machine learning algorithms for patient selection

🔹 Future Pearl: The next generation of albumin research will likely focus on precision medicine approaches rather than population-level effects.

Clinical Pearls and Practical Recommendations

For the Practicing Intensivist

🔹 Pearl 1: In septic shock, albumin benefit appears confined to the sickest patients - those with multiple organ failure and low albumin levels.

🔹 Pearl 2: In cirrhosis, albumin is not just a volume expander - its pleiotropic effects make it uniquely suited for hepatorenal syndrome.

🔹 Pearl 3: Target-directed therapy (albumin >30 g/L) is more rational than fixed dosing regimens.

🔸 Oyster 1: Normal albumin levels don't exclude benefit in septic shock - look at the clinical context, not just the number.

🔸 Oyster 2: In cirrhosis, albumin may be beneficial even when synthetic alternatives seem cheaper - consider the total cost of care.

🔸 Oyster 3: Timing matters - early albumin in appropriate patients may prevent complications rather than just treating them.

Practical Hacks for Clinical Use

The "30-Rule": Target albumin >30 g/L in septic shock
The "1.5-1-Rule": In HRS - 1.5 g/kg day 1, then 1 g/kg maintenance
The "Volume-First Rule": Ensure adequate intravascular volume before albumin
The "Response-Monitor Rule": Assess response at 24-48 hours, not immediately

Conclusions

The evidence for albumin use in critical care has evolved from broad skepticism to targeted application. The ALBIOS trial demonstrated that albumin reduces mortality in septic shock patients, while the ATTIRE trial confirmed its superiority in hepatorenal syndrome. Rather than a universal therapy, albumin should be viewed as a precision medicine tool - highly effective in specific clinical scenarios but not universally beneficial.

Key clinical applications include:

Septic shock with severe organ dysfunction
Hepatorenal syndrome in cirrhotic patients
Spontaneous bacterial peritonitis prevention
Large volume paracentesis support

The future of albumin therapy lies in biomarker-guided, personalized approaches that optimize patient selection and timing of administration.

References

Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370(15):1412-1421.
China L, Freemantle N, Forrest E, et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med. 2021;384(9):808-817.
Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350(22):2247-2256.
Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172-1181.
Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341(6):403-409.
Xu JY, Chen QH, Xie JF, et al. Comparison of the effects of albumin and crystalloid on mortality in adult patients with sepsis and septic shock: a meta-analysis of randomized clinical trials. Crit Care. 2014;18(6):702.
Vincent JL, Russell JA, Jacob M, et al. Albumin administration in the acutely ill: what is new and where next? Crit Care. 2014;18(4):231.
Arroyo V, García-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396-407.
Quinlan GJ, Martin GS, Evans TW. Albumin: biochemical properties and therapeutic potential. Hepatology. 2005;41(6):1211-1219.
Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol. 2006;12(9):1403-1407.

Conflicts of Interest: None declared Funding: None

Sunday, September 7, 2025